免疫治疗肝细胞癌肝移植患者现状和前景展望*

doi:10.3969/j.issn.1672-5069.2024.06.001

Abstract

Zhang Shaobo, Zhang Shugeng, Liu Lianxin. Immunotherapy in hepatocellular carcinoma patients after liver transplantation:Current knowledge and future perspectives[J]. Journal of Practical Hepatology, 2024, 27(6): 801-803.

References

[1] 国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会肝癌专家委员会. 肝细胞癌免疫联合治疗多学科中国专家共识(2023年版). 中华消化外科杂志, 2023, 22(3): 293-315.
[2] 陶开山, 李霄. 中国肝移植术后并发症诊疗规范(2019年版). 器官移植, 2021, 12(2): 129-133.
[3] 王建军, 柴楚星, 孙释然, 等. 肝癌肝移植前降期治疗的研究进展. 中华肝胆外科杂志, 2021, 27(4): 305-309.
[4] Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med, 2023, 20(3): 181-195.
[5] RuffF S M, Manne A, Cloyd J M, et al. Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma. Curr Oncol, 2023, 30(6): 5863-5875.
[6] Laface C, Ranieri G, Maselli F M, et al. Immunotherapy and the combination with targeted therapies for advanced hepatocellular carcinoma. Cancers (Basel), 2023, 15(3):329-332.
[7] Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol, 2020, 21(7): 947-956.
[8] Lawson A, Kamarajah S K, Parrnte A, et al. Outcomes of transarterial embolisation (TAE) vs. transarterial chemoembolisation (TACE) for hepatocellular carcinoma: A systematic review and Meta-analysis. Cancers (Basel), 2023, 15(12):823-826.
[9] 邢皓, 李力, 张全保, 等. 术前免疫治疗对肝移植受者预后的影响. 中华器官移植杂志, 2022, 43(5): 260-266.
[10] Giudicelli H, Roux C, Monsel A, et al. Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation. Clin Res Hepatol Gastroenterol, 2023: 102167.
[11] Nevola R, Delle Femine A, Rosato V, et al. Neoadjuvant and adjuvant systemic therapies in loco-regional treatments for hepatocellular carcinoma: Are we at the dawn of a new era? Cancers (Basel), 2023, 15(11):921-925.
[12] Woo S M, Kimchy A V, Sequeira L M, et al. Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma. Curr Oncol, 2022, 29(12): 9813-9825.
[13] 中国肿瘤整合诊治指南(CACA)-肝癌部分. 肿瘤综合治疗电子杂志, 2022, 8(3): 31-63.
[14] 秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗. 器官移植, 2022, 13(2): 271-276.
[15] Montano-Loza A J, Rodriguez-Perálvarez M L, Pageaux G P, et al. Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation. J Hepatol, 2023, 78(6): 1199-1215.
[16] Gassmann D, Weiler S, Mertens J C, et al. Liver allograft failure after nivolumab treatment-A case report with systematic literature research. Transplant Direct, 2018, 4(8): e376.
[17] Rammohan A, Reddy M S, Farouk M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet? Hepatology, 2018, 67(3): 1166-1168.
[18] Munker S, de Toni E N. Use of checkpoint inhibitors in liver transplant recipients. Uni Eur Gastroenterol J, 2018, 6(7): 970-973.
[19] Jin X, Ma X, Zhao D, et al. Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation. Transl Oncol, 2023, 28: 101603.

Immunotherapy in hepatocellular carcinoma patients after liver transplantation:Current knowledge and future perspectives

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zheng Hao, Zhang Shugeng, Wang Jiabei, et al. Therapeutic strategies for patients with recurrent hepatocellular carcinoma after liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 804-807.
[2]	Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.
[3]	Zeng Wang, Cai Xiaoman, Ge Shang. Enhanced MRI manifestation feature in differential diagnosis of ICC and HCC: A single center study [J]. Journal of Practical Hepatology, 2024, 27(6): 907-910.
[4]	Danba Yuzhen, Cheng Pan. Gd-EOB-DTPA-enhanced MRI scan in diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 911-914.
[5]	Yang Jiaxin, Yang Zijun, Chen Wei. Image quality and diagnostic efficacy of dual-source CT dual-energy TNC technique in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 915-918.
[6]	Wang Lingling, Yao Min, Yao Dengfu. Abnormal expressions of Krüppel-like factors in progression of hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 953-956.
[7]	Li Xiaobin, Liu Bowen, Hu shiping. Lipid metabolic reprogramming in the carcinogenesis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(6): 957-960.
[8]	Zhang Weiping, Ge Hongyan. Pyroptosis and its roles in hepatocellular carcinogenesis [J]. Journal of Practical Hepatology, 2024, 27(5): 797-800.
[9]	Luo Ke, Ding Li, Liu Mei. Cancerous expression of TTF-1, p53 and p63 proteins in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 434-437.
[10]	Yan Zhen, Zhao Bowen, Lin Guoying, et al. Clinical application of imaging three-dimensional visualization technique in guidance of hepatectomy in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(3): 438-441.
[11]	Xu Xu, Shi Yiwen, Fan Jiangao. Treatment of hepatolenticular degeneration:Status and prospective [J]. Journal of Practical Hepatology, 2024, 27(3): 477-480.
[12]	Wei Ye, Wang Shiyu, Ge Gaohua, et al.. Is the magnetic resonance imaging superior to CT scan in the differential diagnosis of hepatic hemangioma and hepatocellular carcinoma? [J]. Journal of Practical Hepatology, 2024, 27(2): 279-282.
[13]	Ye Mengmeng, Deng Zerun, Zhang Tao. Improved benefit of camrelizumab and apatinib combination in the treatment of patients with advanced hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2024, 27(1): 96-100.
[14]	Zhou Li, Ding Yunqing, Yuan Fengying, et al. Diagnostic performance of contrast-enhanced ultrasound in determining qualitatively intrahepatic space-occupying lesions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(6): 903-906.
[15]	Zhang Shugeng, Zhang Shaobo, Zhu Zebin, et al. Early post-operational complications in patients with orthotopic liver transplantation receiving different deceased donors [J]. Journal of Practical Hepatology, 2023, 26(5): 738-741.